Home・Stock List・Erasca Inc

Erasca Inc

Closed

18.55 -3.08

Buy Sell

Overview

Share price change

24h

Current

Min

18.41

Max

18.71

Key metrics
By Trading Economics
Income	-154M -183M
EPS	-0.6
Employees	103
EBITDA	-151M -183M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+20.08% upside

Dividends
By Acuity
Next Earnings	10 Aug 2026

Market Stats
By TradingEconomics
Market Cap	2.4B 5.7B
Previous open	21.63
Previous close	18.55

Erasca Inc Chart

Past performance is not a reliable indicator of future results.

Related News

11 Jul 2026, 23:51 UTC

Cryptocurrency declines amid cautious investor sentiment ahead of key inflation data and geopolitical tensions impacting U.S. markets.

11 Jul 2026, 23:51 UTC

Cryptocurrency prices dip amid geopolitical tensions and cautious investor sentiment ahead of key U.S. inflation reports.

11 Jul 2026, 23:51 UTC

U.S. Stocks Rise Amid AI Enthusiasm and Geopolitical Tensions; Key Inflation Data and China's Declining Retail Sales Loom Ahead.

11 Jul 2026, 23:51 UTC

Cryptocurrency market dips as Bitcoin and Ethereum decline, while U.S. stocks rise ahead of key inflation data and China's retail sales forecast shows potential consumer spending weakness.

11 Jul 2026, 23:51 UTC

Mixed sentiment ahead of NAB Business Confidence report release on July 14, amid ongoing economic concerns and geopolitical uncertainties in Australia.

11 Jul 2026, 23:51 UTC

Correlated Moves

Bitcoin is lower during Saturday's session, continuing a decline since Friday's close. Volatility included a session high earlier before pulling back.

11 Jul 2026, 23:41 UTC

U.S. Retail Sales Ex Autos Expected to Decline 0.1% in June Amid Weakening Consumer Spending and Economic Uncertainty

11 Jul 2026, 23:41 UTC

Philadelphia Fed Manufacturing Index Release on July 16, 2026, Amid Cautious Market Sentiment Due to Geopolitical Tensions and Upcoming Economic Data.

11 Jul 2026, 23:41 UTC

U.S. Retail Sales Expected to Rise 0.3% in June Amid Strong Consumer Spending Trends, According to Bank of America Report

11 Jul 2026, 23:31 UTC

Canada's Housing Starts Data for June 2026 Expected at 260K Amid Economic Volatility and Affordability Concerns.

11 Jul 2026, 23:21 UTC

U.S. Core Producer Prices Expected to Rise 0.4% in June Amid Mixed Global Inflation Signals and Economic Uncertainties

11 Jul 2026, 23:21 UTC

Cautious Market Sentiment Ahead of July 15 Release of NY Empire State Manufacturing Index Amid Geopolitical Tensions and Earnings Reports

11 Jul 2026, 23:21 UTC

Producers Price Inflation (PPI) MoM for June 2026 set to release on July 15, with a forecasted increase of 0.2%, influencing potential Federal Reserve interest rate decisions amid ongoing inflation concerns.

11 Jul 2026, 23:11 UTC

Brazil's Retail Sales Report on July 16, 2026, Expected to Show Volatility Amid Economic Uncertainty and Mixed Previous Results.

11 Jul 2026, 23:01 UTC

Investors Cautiously Await U.S. Core Inflation Rate Release Amid Geopolitical Tensions and Earnings Uncertainty

11 Jul 2026, 23:01 UTC

Upcoming U.S. CPI Release on July 14 Sparks Caution Among Investors Amid Inflation Concerns and Geopolitical Tensions

11 Jul 2026, 23:01 UTC

Investors Brace for July 14 CPI Release Amid High Inflation Concerns and Potential Fed Rate Hike

11 Jul 2026, 23:01 UTC

Investors Brace for July CPI Release Amid Inflation Concerns and Market Volatility

11 Jul 2026, 23:01 UTC

US Core Inflation Rate Expected to Rise 0.3% in June Amid Market Caution and Geopolitical Tensions

11 Jul 2026, 23:01 UTC

U.S. Inflation Rate Expected to Decrease Slightly in June Amid Cautious Market Sentiment and Geopolitical Tensions

11 Jul 2026, 23:01 UTC

Correlated Moves

The Dow Jones Index declined during after-market hours, reflecting cumulative weakness since Friday's close amid broader market sentiment.

11 Jul 2026, 22:53 UTC

Australia's Westpac Consumer Confidence Index set for July 14, 2026 release amid optimistic market sentiment following positive employment figures and easing geopolitical tensions.

11 Jul 2026, 22:53 UTC

Australia's Westpac Consumer Confidence report on July 14, 2026, is expected to show improvement amid positive stock market gains and ongoing inflation concerns.

11 Jul 2026, 22:41 UTC

MBA 30-Year Mortgage Rate Release on July 15 Expected to Reflect Ongoing Inflation and Geopolitical Tensions Impacting Market Sentiment.

11 Jul 2026, 22:31 UTC

Brazil's Central Bank to Provide Key Interest Rate Outlook on July 13, Amid Global Inflationary Trends.

11 Jul 2026, 22:31 UTC

Japan's Machinery Orders Expected to Decline by 4.2% in May Amid Mixed Economic Sentiment and Geopolitical Tensions

11 Jul 2026, 22:21 UTC

Singapore's Upcoming GDP Growth Rate Release Sparks Cautious Optimism Amid Regional Market Trends and Global Economic Factors

11 Jul 2026, 21:41 UTC

South Korea's Unemployment Rate Release on July 14 Expected to Show Increase Amid Economic Concerns and Job Losses.

11 Jul 2026, 21:31 UTC

UK Retail Sales Monitor YoY Forecasts 2.9% Growth Amid Mixed Sentiment and Geopolitical Concerns Ahead of July Release

11 Jul 2026, 20:41 UTC

India's June 2026 Inflation Rate Expected at 4.3%, Amid Rising Prices and Geopolitical Concerns

Peer Comparison

Price change

Erasca Inc Forecast

Price Target

By TipRanks

20.08% upside

12 Months Forecast

Average 22.25 USD 20.08%

High 30 USD

Low 16 USD

Based on 8 Wall Street analysts offering 12 month price targets forErasca Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Erasca Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.